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3. Progress Report 
Objectives. The objectives of the present research are to 1) design and synthe-
size specific substrates for assaying blood proteases, 2) determine the kinetic 
parameters for reaction of various blood proteases with the substrates using purified 
enzymes, 3) study the nature of the extended substrate binding site in plasma proteases 
and 4) synthesize and study the reactivity of peptides corresponding to plasma pro-
tease cleavage sites. 
The goals for the current year were to investigate synthetic methods for thiol 
ester substrates of plasma proteases (objective 1), to determine kinetic parameters 
using the thiol esters (objective 2), and to synthesize peptides corresponding to 
plasma protease cleavage sites (objective 4). 
Thiol Ester Substrates. We have now shown that peptide thiol esters of the type 
RCO-Arg-SR can be used in sensitive assays for the serine proteases involved in clottin.  
Hydrolysis at the thiol ester bond yields a thiol which can be detected with Ellman's 
reagent or other thiol reagents. 
RCO-Arg-SR 	> RCO-Arg-OH + HSR 
As the peptide is hydrolyzed, the absorbance at 410 nm increases as the released thiol 
reacts with Ellman's reagent. Since the thiol esters are good substrates for serine 
proteases and Ellman's reagent can detect low levels of thiol, the proposed substrates 
should be quite sensitive. Recently we have synthesized the thiol ester elastase 
substrate Me0-Suc-Ala-Ala-Pro-Val-SCH2C 6
H
5 . Human leukocyte elastase hydrolyzes this 
compound very effectively and the substrate can be used to assay elastase concentration 
as low as 5 picomolar. 
One significant advantage of thiol ester substrates is their use of P' resides. 
Thus it is possible to design a substrate for an enzyme where only the new N-terminal 
sequence released on cleavage of its substrate is known. Thus a substrate such as 
Ac-Arg-SIle-Val-Gly-Gly-NH 2 could be used to study or detect enzymes that activate 
Factor VII. It should be noted that the Arg-SIle bond in the above substrate differs 
from the Arg-Ile bond in the natural substrate simply by replacement of the NH of the 
peptide bond with a sulfur atom. 
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We have now completed the synthesis of a series of amino acid and peptide thiol 
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Boc-Arg-SPe-i 	 Boc-Arg-SPe-s 
The structures incorporate respectively the side chains of a P i ' valine, leucine 
and isoleucine residue. The activation site of the zymogens of all known serine 
proteases involves cleavage of a Arg-Val, Arg-Ile or Arg-Leu bond. These three 
substrates have allowed us to study the P specifically of activating serine 




and XII 1 . 
The relative k /K- values for all the substrates studied are listed in the 
table. The substrates
cat m  were studied at pH 7.5, 0.1 M HEPES buffer, 0.01 M CaC1 2 , 
9.8% v/v DMSO at 30 ° C with 4 clotting enzymes and trypsin. Only relative values 
are given in this short report, although all the kinetic parameters have been 
determined and will be reported in a full paper. 
One highlight of the data is the discovery of two good synthetic substrates for 
Factor IXa
. Both the substrates (Z-Phe-Arg-SBu-i and Z-Trp-Arg-SBu-i) have a P 2 
aromatic residue. No other good synthetic substrates exist for Factor IX a. These 
substrates will be useful in future studies of Factor IXa . 
In addition to the Factor IX substrates we discovered several excellent 
Factor XI sustrates. Neither Fac
a  tor IX or XI have previously been studied in 
any detail with synthetic substrates. We
a 
 are now synthesizing tripeptide thiol 
esters to continue our subsite mapping studies of these two enzymes. In addition, 
we expect to study other enzymes such as Factor XII a in the near future. 
Peptides Corresponding to Plasma Protease Cleavage Sites. Serine proteases such 
as Factors IX, XI and XII probably recognize both a specific amino acid sequence 
and a specific
a 
 coaormation in their natural substrates. As an initial working 
hypothesis, I have assumed that recognition of the sequence is the most important and 
that synthetic substrates with the appropriate sequence should be fairly specific 
for individual enzymes. Thus an appropriate Factor IX substrate would be something 
with the sequence RCO-Gln-Val-Val-Arg*Ile-Val-Gly-NH 2 t*indicates the cleavage site 
in Factor X, Factor IX' substrate). Initially we have decided to concentrate all 
of our effort on Factor
a 
 IXa , XI a and XII substrates. Very little research with 
synthetic substrates has been reported taus far with these enzymes and thus' we may 
be able to gain new insights about the active sites of these enzymes. Some of the 
peptides which we are in the process of synthesizing are listed below: 
Factor IXa substrate (sequence•of Factor X 
cleavage site) 
Abz-Gln-Val-Val-Arg*Ile-Val-Gly-Nba 






Factor XII substrate (P l -P,' corresponds to Factor'XI clevage site) 
Abz-A10Ala-Ala-Arg*Ite-Val-Gly-Nba 
In each case the N-terminus of .the peptide is blocked with a 2-aminobenzoyl 
(Abz) group and the C-terminus is protected as the 4-nitrobenzyl amide (Nba). The 
rate of enzymatic hydrolysis for each of these substrates will be monitored using 
fluorometric techniques. The aminobenzoyl group is fluorescent and the nitrobenzyl 
group is a quenching group. Upon hydrolysis, the quenching group is separated from 
the fluorescent group such that the latter freely fluoresces after excitation at an 
appropriate wavelength. The rate of increase in fluorescence corresponds to the 
rate of hydrolysis of the peptide. 
For the last year we have been involved .exclusively in synthesis. We have now 
completed the synthesis of 6-8 peptides with sequences corresponding to Factor IX a 
 and XI cleavage sites. We are now in the process of doing the kinetic studies 
with these peptides. 
Research Goals for the Coming Year  
1) Measure kinetics with the dipeptide thiol ester substrate using enzymes such 
as plasmin, Factor XII a , kallibrein and Cl;. Synthesize tripeptide thiol ester sub- 
trates and use them to map the extended substrate binding site of Factor IXa and XI a . 
2) Continue the synthesis of fluorescent peptide substrates corresponding to Factor 
IX and XI cleavage sites. Measure the kinetics of their reaction with various 
blo
a  od clotting serine proteases. 
Significance. The plasma proteases that are being investigated in this re-
search are involved in a number of important physiological process such as blood 
coagulation, fibronolysis and kinin formation. A number of clinical assays are 
used on the determination of the activity of various plasma proteases mostly using 
clotting assays. The synthetic substrates which will be developed in this research 
should be quite sensitive and specific and should allow assays to be developed for 
plasma component: which are impossible currently due to the complex nature of clotting 
assays. Since they are spectrophotometrically or spectrofluoromefrically based, 
they would be useable in most clinical labs, even those without extensive instru-
mentation. 
The proposed research would lead to a better understanding of the nature of the 
active site structures of various plasma proteases and how they are affected by 
various plasma modulators such as phospholipids. This should give us a better 
understanding of various coagulation disorders. This in turn could lead to new 
avenues of therapy where various specific activators or inhibitors are used to 
control the activity of certain plasma proteases. 
The undersigned agrees to accept responsibility for the scientific and tech-
nical conduct of the project and for provision of required progress reports if a 
grant is awarded as the result of this application. 
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